Down 9.27%: MANGALAM.BO Mangalam Drugs BSE 31.92 pre-mkt Jan 2026, watch 22.70
MANGALAM.BO stock fell 9.27% to INR 31.92 in pre-market trade on 09 Jan 2026, making it one of today’s top losers on the BSE. The move follows heavy relative volume of 3.38 versus a five-week average and pushes the share nearer to its 52-week low of INR 22.70. Investors should note negative trailing EPS of -12.51 and a negative PE of -2.95, which underline profit pressure. This piece outlines valuation, technical levels, a Meyka AI grade, and price forecasts to frame near-term trade and risk.
MANGALAM.BO stock: Price action and pre-market movers
MANGALAM.BO opened and traded at INR 31.92 in pre-market on 09 Jan 2026, down INR 3.26 or 9.27% versus the previous close of INR 35.18. Volume for the session stood at 20,441 shares against an average of 38,735, producing a relative volume of 3.38, which signals above-average trading interest. The one-day decline follows a YTD drop of 50.19%, marking weak sentiment into the new year.
Fundamentals and valuation for MANGALAM.BO stock
Mangalam Drugs & Organics shows a market cap of INR 584,535,426 and book value per share of INR 80.58, leading to a low price-to-book of 0.46. The company reports EPS -12.51 and PE -2.95, reflecting losses. Debt to equity is 0.74, and current ratio is 0.91, which suggests constrained short-term liquidity. Price-to-sales at 0.22 signals low revenue multiple versus sector peers.
Technical picture and short-term levels for MANGALAM.BO stock
The technicals show RSI 43.35, ADX 58.17 indicating a strong trend, and MACD histogram positive at 1.81. Key resistance sits at the 50-day average INR 39.66 and the mid-Bollinger band near INR 25.21. Immediate support is the year low INR 22.70, with the next support near INR 28.00 from recent price clusters. Traders should watch a break below INR 22.70 or a reclaim above INR 39.66 for directional confirmation.
Meyka AI rates MANGALAM.BO with a score out of 100
Meyka AI rates MANGALAM.BO with a score out of 100: 55.02 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects mixed signals: attractive valuation ratios but weak profitability and stretched inventory days, so the model recommends caution. These grades are informational only and not financial advice.
Meyka AI’s forecast model projects price targets for MANGALAM.BO stock
Meyka AI’s forecast model projects a monthly target of INR 18.58 and a one-year target of INR 40.92 for MANGALAM.BO stock. Versus the current price INR 31.92, the one-year forecast implies an upside of 28.20% and the monthly forecast implies a near-term downside of -41.80%. Forecasts are model-based projections and not guarantees, and they reflect short-term volatility plus recovery scenarios.
Sector context and risks for MANGALAM.BO stock
Mangalam operates in the Drug Manufacturers – Specialty & Generic industry inside Healthcare, where average PE is about 41.12 and average PB is 4.92, making Mangalam’s valuation materially lower. Major risks include negative earnings, long days of inventory (258.55 days), a stretched cash conversion cycle, and interest coverage at -0.38. Opportunities include a wide product pipeline and low price-to-sales for recovery if margins improve.
Final Thoughts
MANGALAM.BO stock is a clear pre-market loser on 09 Jan 2026, down 9.27% to INR 31.92, with trading volume above average and sentiment weak into the year. Fundamentals show low valuation multiples, with PB 0.46 and P/S 0.22, but loss-making operations and inventory inefficiency raise solvency concerns. Technically, watch INR 22.70 as key support and INR 39.66 as near-term resistance. Meyka AI’s one-year forecast of INR 40.92 implies a 28.20% upside, while the monthly projection of INR 18.58 flags a -41.80% near-term risk. Given a Meyka grade of C+ (55.02) and mixed signals, we frame MANGALAM.BO stock as a cautious hold for risk-tolerant investors. Active traders should use strict stops, and long-term investors should wait for margin improvement and clearer cash flow before adding exposure. For live quotes and tools, see the company site and BSE quote and the Meyka stock page for updates and alerts.
FAQs
Why did MANGALAM.BO stock fall in pre-market trade today?
MANGALAM.BO stock fell due to negative sentiment, above-average relative volume of 3.38, and ongoing loss-making results (EPS -12.51). Traders reacted to weak fundamentals and inventory strain, pushing the price down to INR 31.92 in pre-market.
What are the key support and resistance levels for MANGALAM.BO stock?
Key support is the 52-week low at INR 22.70 and a near-term cluster around INR 28.00. Main resistance is the 50-day average at INR 39.66 and psychological resistance near INR 40.00.
What does Meyka AI forecast imply for MANGALAM.BO stock?
Meyka AI’s model projects INR 40.92 for one year, implying +28.20% upside versus INR 31.92 now. The monthly model shows INR 18.58, implying near-term downside. Forecasts are model-based and not guarantees.
Is MANGALAM.BO stock a buy based on valuation?
Valuation looks cheap with PB 0.46 and P/S 0.22, but negative earnings and liquidity metrics raise risk. Meyka AI assigns a C+ grade and suggests a HOLD until margins and cash flow improve.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
